Lisa Kriegl
banner
lisakriegl.bsky.social
Lisa Kriegl
@lisakriegl.bsky.social
MD, all things infectious disease
Reposted by Lisa Kriegl
Triazoles versus Echinocandins for the first-line treatment of invasive pulmonary aspergillosis ? A propensity score weighted multicenter study

✅ Just Accepted
🔗 https://bit.ly/3LV7LYP
November 23, 2025 at 12:14 AM
Happy to share our latest work: Empirical antifungals in influenza-ARDS ICU patients cut IAPA risk (7.7% vs 20.4%), but no survival benefit. RCTs and biomarkers needed ❤️‍🔥
September 23, 2025 at 9:22 PM
Reposted by Lisa Kriegl
Pulmonary Co-Infection of Pneumocystis jirovecii and Aspergillus species

Hatzl and colleagues in @ofidjournal.bsky.social

academic.oup.com/ofid/advance...
January 13, 2025 at 2:46 PM
Reposted by Lisa Kriegl
✨📄 What about the untapped therapeutic potential of the immune response in invasive aspergillosis ? Here’s some rational, pre-clinical and clinical evidence. Huge thanks to our amazing 🌍 team!
🔗 bit.ly/46kajHr
@simonfeys.bsky.social @agocarvalho.bsky.social @martinhoenigl.bsky.social
September 4, 2025 at 7:57 AM
Reposted by Lisa Kriegl
Our newest review is published @nature.com Reviews Microbiology! 🥳
Together with Julian Naglik, we discuss the interplay of #Candida albicans, the host, and the microbiota during commensalism and pathogenicity. 🍄🦠
Check out the article here 👉 www.nature.com/articles/s41...
@leibniz-hki.de
Commensalism and pathogenesis of Candida albicans at the mucosal interface - Nature Reviews Microbiology
In this Review, Hube and colleagues overview the commensal and pathogenic lifestyles of Candida albicans, focusing on how the fungus transitions between these two states, the fungal and host factors i...
www.nature.com
April 17, 2025 at 12:01 PM